Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its executive management team's participation in two investor conferences. The Cowen 42nd Annual Virtual Healthcare Conference is scheduled for March 9, 2022, at 2:50 p.m. ET, while the Oppenheimer’s 32nd Annual Healthcare Conference will take place on March 16, 2022, at 1:20 p.m. ET. Interested parties can access the live webcasts on the Aurinia corporate website under the Investors section.

Aurinia is focused on treating serious diseases, having launched LUPKYNIS™, the first FDA-approved oral therapy for active lupus nephritis in January 2021.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presentations at two upcoming investor conferences including:

• Cowen 42^nd Annual Virtual Healthcare Conference corporate presentation on Wednesday, March 9, 2022 at 2:50 p.m. ET. Link here
• Oppenheimer’s 32nd Annual Healthcare Conference corporate presentation on Wed, March 16, 2022 at 1:20 p.m. ET. Link here

To participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005982/en/

Investor and Media:

Dana Lynch

Investor Relations and Corporate Communications

dlynch@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

When will Aurinia Pharmaceuticals present at the Cowen Virtual Healthcare Conference?

Aurinia Pharmaceuticals will present at the Cowen 42nd Annual Virtual Healthcare Conference on March 9, 2022, at 2:50 p.m. ET.

What date is the Oppenheimer 32nd Annual Healthcare Conference where AUPH will present?

The Oppenheimer 32nd Annual Healthcare Conference is scheduled for March 16, 2022, at 1:20 p.m. ET.

How can I access the live webcasts for AUPH's presentations?

You can access the live webcasts for Aurinia's presentations under the 'Investors' section on their corporate website.

What is LUPKYNIS and when was it launched by Aurinia Pharmaceuticals?

LUPKYNIS™ is the first FDA-approved oral therapy for active lupus nephritis, launched by Aurinia Pharmaceuticals in January 2021.

Where is Aurinia Pharmaceuticals headquartered?

Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia.